nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acknowledgement of reviewers 2016
|
|
|
2017 |
81 |
2 |
p. 425 |
artikel |
2 |
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)
|
Kagawa, Shunsuke |
|
2017 |
81 |
2 |
p. 387-392 |
artikel |
3 |
A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
|
Tanaka, Ichidai |
|
2017 |
81 |
2 |
p. 339-345 |
artikel |
4 |
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis
|
Hanke, Nina |
|
2017 |
81 |
2 |
p. 291-304 |
artikel |
5 |
A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia
|
Kim, Sung-Yong |
|
2018 |
81 |
2 |
p. 393-398 |
artikel |
6 |
B7-H3 in tumors: friend or foe for tumor immunity?
|
Li, Gen |
|
2018 |
81 |
2 |
p. 245-253 |
artikel |
7 |
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study
|
Kataoka, Yuki |
|
2017 |
81 |
2 |
p. 333-337 |
artikel |
8 |
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
|
Markus, Richard |
|
2017 |
81 |
2 |
p. 419 |
artikel |
9 |
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
|
Jong, Jan de |
|
2017 |
81 |
2 |
p. 423 |
artikel |
10 |
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
|
Chen, Shang-Chiung |
|
2017 |
81 |
2 |
p. 421-422 |
artikel |
11 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
|
Zhou, Xinna |
|
2017 |
81 |
2 |
p. 365-372 |
artikel |
12 |
Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells
|
Fedorchuk, Olexandr |
|
2017 |
81 |
2 |
p. 373-385 |
artikel |
13 |
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
|
Jiang, Qi |
|
2017 |
81 |
2 |
p. 315-323 |
artikel |
14 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
|
Phua, Lee Cheng |
|
2017 |
81 |
2 |
p. 277-289 |
artikel |
15 |
Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
|
Mistry, Hitesh B. |
|
2017 |
81 |
2 |
p. 325-332 |
artikel |
16 |
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients
|
Schoch, L. K. |
|
2017 |
81 |
2 |
p. 347-354 |
artikel |
17 |
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia
|
Völler, Swantje |
|
2017 |
81 |
2 |
p. 305-314 |
artikel |
18 |
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
|
Chan, Emily |
|
2017 |
81 |
2 |
p. 355-364 |
artikel |
19 |
Positioning of proteasome inhibitors in therapy of solid malignancies
|
Roeten, Margot S. F. |
|
2017 |
81 |
2 |
p. 227-243 |
artikel |
20 |
Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic
|
Ishikawa, Motoaki |
|
2018 |
81 |
2 |
p. 399-411 |
artikel |
21 |
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
|
Shien, Tadahiko |
|
2017 |
81 |
2 |
p. 269-275 |
artikel |
22 |
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations
|
Liu, Xiaojun |
|
2017 |
81 |
2 |
p. 255-267 |
artikel |
23 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer
|
Williams, Grant R. |
|
2017 |
81 |
2 |
p. 413-417 |
artikel |